Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that ...
ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA ...
Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...
AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband ...
Nutriband (NTRB) files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for ...
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...
ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback